Vanda Pharmaceuticals/VNDA

$4.12

-3.5%
-
1D1W1MYTD1YMAX

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Ticker

VNDA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mihael Polymeropoulos

Employees

203

Headquarters

Washington, United States

VNDA Metrics

BasicAdvanced
$237.05M
Market cap
93.96
P/E ratio
$0.04
EPS
0.77
Beta
-
Dividend rate
$237.05M
0.76919
$7.00
$3.30
1.85M
4.937
4.921
-29.441
0.39%
0.47%
0.45%
93.957
1.231
0.435
0.56
19.09
-24.27%
-58.19%
-8.1%
-53.11%

What the Analysts think about VNDA

Analyst Ratings

Majority rating from 1 analysts.
Hold

Price Targets

Average projection from 1 analyst.
27.43% upside
High $5.25
Low $5.25
$4.12
Current price
$5.25
Average price target

VNDA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5.3% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$45.2M
16.49%
Net income
$-2.4M
-2,500%
Profit margin
-5.3%
-2,220%

VNDA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 55.56%
QuarterlyAnnual
Q4 22
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.12
$0.03
-
-$0.04
-
Expected
$0.08
-$0.13
-$0.04
-$0.09
$0.05
Surprise
50%
-123.08%
-
-55.56%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals (VNDA) has a market cap of $237.05M as of April 15, 2024.

What is the P/E ratio for Vanda Pharmaceuticals stock?

The price to earnings (P/E) ratio for Vanda Pharmaceuticals (VNDA) stock is 93.96 as of April 15, 2024.

Does Vanda Pharmaceuticals stock pay dividends?

No, Vanda Pharmaceuticals (VNDA) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Vanda Pharmaceuticals dividend payment date?

Vanda Pharmaceuticals (VNDA) stock does not pay dividends to its shareholders.

What is the beta indicator for Vanda Pharmaceuticals?

Vanda Pharmaceuticals (VNDA) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Vanda Pharmaceuticals stock price target?

The target price for Vanda Pharmaceuticals (VNDA) stock is $5.25, which is 27.43% above the current price of $4.12. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Vanda Pharmaceuticals stock

Buy or sell Vanda Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing